FindTrial
Sign In

Genetic Study of Lung Cancer and Identification of Potent and Safe Ayurvedic Combination for Lung Cancers

â??Corelation of Prakriti & Sara with Germline mutations in Lung cancers and Identification of potent Ayurvedic compounds against lung carcinomaâ??

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/02/031607
Enrollment
50
Registered
2021-02-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J988- Other specified respiratory disorders Health Condition 2: J988- Other specified respiratory disorders

Interventions

Intervention1: Curcuma longa: Haridra (Curcuma longa)

Sponsors

Institute of Medical Sciences BHU
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. From 1 Year to 80 Years of patients. 2. Patients who fulfilled the criteria of Diagnostic features of Lung cancer 3. Clinically diagnosed Lung Cancer patient including both small cell and non-small cell lung cancer 4. Both male and female patients

Exclusion criteria

Exclusion criteria: 1. Patient with another type of cancer along with lung cancer 2. Patients with certain genetic syndromes which are sometimes associated with diabetes mellitus e.g. Downâ??s syndrome, Klinefelterâ??s syndrome, Turnerâ??s syndrome etc.

Design outcomes

Primary

MeasureTime frame
Germ line mutations and other Genetic factors (methylations, miRNAs) will be screened in lung cancers from Indian populations.Timepoint: I-year: Assessment of Sara and Prakriti,Germline mutations, Screening and Identification of potent drugs/kinase inhibitors for lung cancers will be studied on lung cancer mutant and induced mice models and analyzed in CAL cell lines. II-year: Identified mutations will be screened in controls. Drugs studies on mice will be done. III-year: Further more samples and controls will be analyzed. Funtional analysis of drugs on cell lines will be analyzed.—

Secondary

MeasureTime frame
II-year: Screening and Identification of potent drugs/kinase inhibitors for lung cancers will be studied on CAL cell lines. III-year: Screening and Identification of potent Ayurvedic compounds/formulations on various lung carcinoma cell lines in order to identify safe and effective cure/immunomodulatory effect for lung cancers. And find out the associations of Prakriti and Sara with lung cancers and genetic mutations in an Indian population Timepoint: 2 to 3 years—

Countries

India

Contacts

Public ContactMamta Tiwari

Institute of Medical Sciences BHU

Dr.anubhu@gmail.com09918748874

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026